Education
About Us
Working with TipRanks
Follow Us
Timothy Noyes Insider Profile
4 Followers
Timothy Noyes, President & CEO, Director at Protara Therapeutics, holds 0.00 shares in Aerovate Therapeutics (Ticker: AVTE), holds 0.00 shares in Protara Therapeutics (Ticker: TARA).
Timothy Noyes has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Timothy Noyes does not currently own shares as a corporate insider.
A breakdown of Timothy Noyes's holdings
Insider Roles
Roles that Timothy Noyes holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Timothy Noyes
Timothy Noyes's Trading History
Protara Therapeutics
Feb 20, 2018
President & CEO, Director
Uninformative Sell
6.32K
$0.00
Aerovate Therapeutics
May 17, 2024
CEO, Director
Uninformative Buy
21.40K
$0.00
List of latest transactions for each holding click on a transaction to see Timothy Noyes's performance on stock
You May Also Like
Timothy Noyes insider profile FAQ
What is the percentage of profitable transactions made by Timothy Noyes?
The percentage of profitable transactions made by Timothy Noyes is ―.
What is the average return per transaction made by Timothy Noyes?
The average return per transaction made by Timothy Noyes is ―.
What stocks does Timothy Noyes hold?
Timothy Noyes holds: TARA, AVTE stocks.
What was Timothy Noyes’s latest transaction?
Timothy Noyes latest transaction was an Uninformative Buy of $21.40K.
What was Timothy Noyes's most profitable transaction?
Timothy Noyes’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Timothy Noyes's role in Protara Therapeutics?
Timothy Noyes's role in Protara Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.